GSPT1 and cancer: The recent discovery of thalidomide analogs that degrade G1 to S phase transition 1 (GSPT1) via the CRL4CRBN ubiquitin ligase highlighted GSPT1 as a novel potential therapeutic target in the treatment of cancer (1).